United Therapeutics shareholders approve 1.5M-share equity plan, elect all directors

Filed June 29, 2026 · Period ending June 26, 2026 · ~1 min read

Key Changes

• medium

  Shareholders approved a new 2026 equity plan adding 1,500,000 shares to the 2,413,730 remaining under the prior plan, creating a pool of ~3.9M shares for future grants (71.5% support, 27.8% against).

  Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →
• low

  All twelve directors elected for one-year terms with support ranging from 89.3% to 99.9%; three directors (Causey, Patusky, Sullivan) received elevated opposition of 7.7%–10.7%.

  Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →
• low

  Say-on-pay approved with 97.1% support (35.2M for, 1.0M against), indicating strong shareholder satisfaction with executive compensation practices.

  Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →